Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib With or Without Other Agents Versus Gemcitabine or Capecitabine in Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma
2016-002218-36Phase 2Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of abemaciclib in pancreatic adenocarcinoma (PDAC) (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Primary endpoint (Stage 1). Started Nov 2016; status: terminated.
02
Drugs
abemaciclib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2016-002218-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002218-36.